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Ribosomal S6 kinase 1 (S6K1) is a major mTOR
downstream signaling molecule that regulates cell
size and translation efficiency. Here, we report that
short isoforms of S6K1 are overproduced in breast
cancer cell lines and tumors. Overexpression of
S6K1 short isoforms induces transformation of
human breast epithelial cells. The long S6K1 variant
(Iso-1) induced opposite effects. It inhibits Ras-
induced transformation and tumor formation, while
its knockdown or knockout induces transformation,
suggesting that Iso-1 has a tumor-suppressor
activity. Furthermore, we found that S6K1 short iso-
forms bind and activate mTORC1, elevating 4E-BP1
phosphorylation, cap-dependent translation, and
Mcl-1 protein levels. Both a phosphorylation-defec-
tive 4E-BP1 mutant and the mTORC1 inhibitor rapa-
mycin partially blocked the oncogenic effects of
S6K1 short isoforms, suggesting that these aremedi-
ated by mTORC1 and 4E-BP1. Thus, alternative
splicing of S6K1 acts as a molecular switch in breast
cancer cells, elevating oncogenic isoforms that acti-
vate mTORC1.
INTRODUCTION
The PI3K/Akt/mTOR pathway is one of the major signaling path-
ways hyperactivated in many cancers and leads to uncontrolled
proliferation, increased survival, motility, and invasiveness of
cancer cells (Mamane et al., 2006; Manning and Cantley, 2007;
Yuan and Cantley, 2008). mTOR resides in two distinct com-
plexes: mTOR complex-1 (mTORC1) and complex-2 (mTORC2)
(Zoncu et al., 2011). mTORC1 core contains mTOR, Raptor, and
G-b-L and is considered to be sensitive to rapamycin. mTORC2
contains Rictor, as themTOR partner instead of Raptor, and, de-
pending on the cell type, is less sensitive to rapamycin (Sarbas-
sov et al., 2004, 2006). The best-characterized substrates of
mTORC1 are S6 Kinase 1(S6K1) and eukaryotic initiation factorC4E (eIF4E)-binding protein 1 (4E-BP1), while Akt is a substrate
of mTORC2 (Sarbassov et al., 2006; Shiota et al., 2006). Several
components of the mTOR signaling cascade have been identi-
fied as oncogenes or tumor suppressors that activate or repress
this pathway, respectively (Zoncu et al., 2011; Shaw and Cant-
ley, 2006). Among the two well-characterized mTORC1 sub-
strates, S6K1 and 4E-BP1, the latter has been shown to be
important for efficient protein translation, proliferation, and onco-
genic transformation (Hsieh et al., 2010; Ohanna et al., 2005; She
et al., 2010). S6K1 has been implicated in the regulation of cell
size (Ohanna et al., 2005), and its role in transformation is contro-
versial; in some reports, it seems dispensable for transformation
(Hsieh et al., 2010), while in others it appears to be required (Al-
liouachene et al., 2008). A link between S6K1 function and
cancer was suggested by the finding that RPS6KB1, the gene
encoding for S6K1, resides in the chromosomal region 17q22-
17q23, which is often amplified in breast and lung cancers (Be-
pler and Koehler, 1995; Monni et al., 2001). However, direct
evidence that S6K1 expression or activity is sufficient to lead
to cellular transformation is lacking. We have previously reported
that the splicing factor oncoprotein SRSF1 is upregulated and
in some cases amplified in several types of tumors, including
breast and lung (Karni et al., 2007). SRSF1 modulates the
splicing of RPS6KB1, which encodes S6K1 in both mouse and
human (Karni et al., 2007). Furthermore, SRSF1 activates the
mTORC1 pathway, which phosphorylates S6K1 downstream
of Akt (Karni et al., 2008). The spliced variants of S6K1 yield
a long active kinase p85/p70 S6K1 (will be referred to as Iso-1)
and shorter splicing variants (will be referred to as Iso-2 inmouse
and h6A and h6C in human). We have shown previously that
SRSF1 increases the expression of the shorter S6K1 isoform,
and that this isoform possesses oncogenic activity and can
transform immortal mouse fibroblasts (Karni et al., 2007).
In this study, we examine the oncogenic and signaling activi-
ties of S6K1 splicing isoforms and their expression in cancer.
Our findings suggest that while Iso-1 is tumor suppressive
in vitro and in vivo and can block Ras-induced transformation,
the short kinase inactive S6K1 splicing isoforms possess onco-
genic properties. We show that the short isoforms of S6K1 bind
mTOR and activate mTORC1, leading to increased 4E-BP1
phosphorylation, cap-dependent translation, and upregulationell Reports 3, 103–115, January 31, 2013 ª2013 The Authors 103
Figure 1. Increased Expression of Human
S6K1 Short Variants 6A and 6C in Breast
Cancer Cell Lines and Tumors
(A) Schematic representation of RPS6KB1 pre-
mRNA and its splicing isoforms. Isoform-1(en-
coding for p70/p85 S6K1 protein) is composed of
15 exons (blue boxes). S6K1 mouse spliced
variant-2 (Iso-2) contains three alternative exons
between exon 6 and 7: a, b, c (red boxes), a
different polyadenylation site and 30 UTR region
(yellow area), and a stop codon in exon 6C. Human
short S6K1 isoforms, h6C and h6A, lack the
alternative 6b exon and contain a combination of
two alternative exons: exon a followed by 30 UTR
or followed by exon c. In both cases, a stop codon
in exon a terminates translation at the same amino
acid and both transcripts give rise to one protein,
h6A. The other isoform includes only exon 6C
followed by a poly(A) tail and encodes a protein
with a different C terminus. All S6K1 short variants
are identical up to the sixth exon and differ from
Iso-1 and from each other in their C terminus.
(B) RNA from the indicated immortalized breast
cell lines (HMLE,MCF-10A) or breast cancer cell
lines (MCF-7, BT474, T47D, ZR-75-1, MDA-MB-
231, MDA-MB-468, SUM149, SUM159) was ex-
tracted and the levels of S6K1 h6A and h6C
short isoforms and Iso-1 were detected by RT-
PCR with primers specific for each isoform. The
splice variants are indicated by boxes at the right
side of each transcription variant.
(C and D) qRT-PCR quantitation of S6K1 isoforms:
Iso-1, h6A, and h6C. Quantitation was done on
total RNA extracted from breast cell lines (C) or
tumors (D). All samples were normalized to b-actin
mRNA levels and to the average expression of the
immortal breast cell lines (HMLE and MCF-10A).
Error bars represent SD of three repeats.
See also Figure S1.of the antiapoptotic proteinMcl-1. Furthermore,mTORC1activa-
tion is critical for the oncogenic activity of S6K1 short isoforms as
themTORC1 inhibitor rapamycin or expression of a phosphoryla-
tion-defective mutant of 4E-BP1 (Hsieh et al., 2010; She et al.,
2010) partially inhibit the oncogenic properties of these isoforms.
Taken together, our results suggest that S6K1 alternative splicing
acts as a switch between a tumor suppressor protein and an on-
coprotein, which is deregulated in breast cancer and modulates
mTORC1 activity.
RESULTS
S6K1 Short Isoforms Are Upregulated in Breast Cancer
Cell Lines and Tumors
The gene RPS6KB1 encoding for p85/p70 S6K1 can be alterna-
tively spliced to form a number of truncated isoforms. In mouse
cells, the splicing factor SRSF1 induces the inclusion of three
additional exons (a-b-c) located between exon 6 and 7 (Fig-104 Cell Reports 3, 103–115, January 31, 2013 ª2013 The Authorsure 1A). By PCR, cloning, and
sequencing, we have discovered that in
human there are two alternative exons inthis region: a and c, which can be included together or individu-
ally generating two protein isoforms that we have termed h6A
and h6C (Figures 1A; Figures S1D and S1E; Table S1). All of
these isoforms in mouse or human that include combinations
of exons 6 (a–c) are termed S6K1 short isoforms. Inclusion of
the alternative exons mentioned above results in exposure of
alternative polyadenylation sites and alterations in the reading
frame that, in turn, generate a stop codon in exon 6c in mouse
and exons 6a or 6c in humans. The presence of these stop
codons creates transcripts containing approximately half of the
original S6K1 coding sequence (Iso-1), and lacking more than
half of the conserved kinase domain (Figure 2A).
In all of these alternative splicing events, the presence of a pol-
yadenylation sequence, and in the case of h6A also a premature
stop codon (PTC) located less then 55 bp from the next exon
junction complex, prevents degradation of the generated tran-
scripts by the Nonsense Mediated Decay (NMD) mechanism
(Figures 1A and S1E) (Schoenberg andMaquat, 2012). We found
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Figure 2. S6K1 Short Isoforms Enhance Transformation of Breast Epithelial Cells
(A) The predicted protein structure of mouse and human RPS6KB1 splicing isoforms. All isoforms contain Raptor binding motif mTOR-signaling (TOS) at the N
terminus (white boxes) and a lysine residue (K123) at the ATP binding site in the catalytic domain that is essential for its protein kinase activity. S6K1 isoform-1
kinase dead version (Iso-1 K123 > A) contains a lysine to alanine (K123A) substitution. S6K1 short isoforms lack 6 out of the 12 conserved kinase helical domains
as well as the C-terminal autoinhibitory domain, which harbors the mTOR activatory phosphorylation site at threonine 389.
(B) MCF-10A cells were transduced with retroviruses encoding for the indicated S6K1 isoforms and protein extracts subjected to western blotting. Membranes
were probed with a monoclonal antibody against the N0 terminus of S6K1 to detect the endogenous and exogenous isoforms. b-actin was analyzed as a loading
control.
(C) Pools of MCF-10A cells transduced with the indicated retroviruses as in (B) were seeded into soft agar in duplicates and colonies were allowed to grow for
14 days. Data represent the average number ± SD of colonies per well. n = 2. *p = 0.0049 **p % 0.005 relative to empty vector. The results shown are
a representative experiment out of three individual experiments.
(D)MCF-10Apools of cells transducedwith the indicated retroviruses as in (B)were stimulated tomigrate by physical wounding of cells seeded inmonolayer. n = 3.
(E) Representative images of the wound area of cells described in (D).
See also Figure S2.
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that while in immortal breast cells (MCF-10A, HMLE) the expres-
sion of S6K1 short isoforms is relatively low, in breast cancer cell
lines inclusion of exons 6a and6c is significantly increased, espe-
cially in metastatic breast carcinoma cell lines (Figures 1B and
S1A). Indeed, while in both primary and immortal breast cells
S6K1 short protein isoforms were hardly detected at the protein
level, in breast cancer cell lines elevated protein levels of S6K1
short isoforms were detected (Figure S1C) (Karni et al., 2007;
Rosner and Hengstschla¨ger, 2011). In human breast tumor
samples, we found elevated expression of S6K1, h6A, and h6C
isoforms compared to the immortal breast cell lines (Figures
1D, S1F, and S1G). Interestingly, whereas most analyzed breast
cancer cell lines and tumor samples presentedhigh expression of
S6K1 short isoforms, we did not find elevated expression of the
full-length isoform Iso-1 in most tumors (Figures 1B–1D). Two
of the cell lines that showed elevated Iso-1 expression (MCF-7,
BT474) possess amplification of theRPS6KB1 gene, and, except
for MCF-7, all tumors and cell lines showed an increase in short
isoforms/Iso-1 ratio (Figures S1F and S1G), indicating that an
alternative splicing switch in S6K1 occurs in breast cancer.
All S6K1 protein isoforms are identical in their N terminus but
share only partial homology in their kinase domain and differ
from each other in their C terminus. Iso-1, Iso-2, h6A, and h6C
contain distinct sequences in their C terminus consisting of
330, 121, 12, or 24 amino acids, respectively (Figure 2A).
S6K1 Short Isoforms Enhance Motility and Anchorage-
Independent Growth
We sought to examine the oncogenic activity of S6K1 isoforms
in human breast epithelial cells. We found that Iso-2, h6A, and
h6C were able to transform human immortal breast MCF-10A
cells and mouse NIH 3T3 cells enabling them to form colonies
in soft agar despite the relatively low expression of the short iso-
forms in comparison to Iso-1 (Figures 2B, 2C, and S2A–S2C).
The kinase dead version of Iso-1 (Iso-1 K123 > A) enhanced
transformation and increased the ability of MCF-10A and NIH
3T3 cells to form colonies in soft agar as well (Figures 2C and
S2C). An in vitro kinase assay using S6 as a substrate shows
that the short isoform Iso-2 and the kinase dead K123 >A version
of Iso-1 have no kinase activity (Figure S2G). The oncogenic
effects of S6K1 short isoforms did not require a functional kinase
activity since all short S6K1 isoforms share truncated kinase
domains and cannot phosphorylate ribosomal protein S6, or
mTOR, both known S6K1 substrates (Figures S2E–S2G and
5A) (Chiang and Abraham, 2005; Holz and Blenis, 2005). In
contrast to the expression of S6K1 short isoforms, overexpres-
sion of Iso-1, the long active kinase, did not enhance colony
formation in soft agar and even reduced the basal level of colony
formation (Figure 2C).
One characteristic of cellular transformation is enhancement
of cell motility (Hanahan and Weinberg, 2011). MCF-10A cells
expressing the shorter isoforms or the kinase dead version of
Iso-1 (Iso-1 K123 > A) showed accelerated migration rate com-
pared to cells transduced with S6K1 Iso-1 or the empty vector
in a tissue culture wound healing assay (Figures 2D and 2E). In
order to exclude the possibility that these effects are the result
of changes in proliferation, we measured the proliferation rate
of the cells. Cells overexpressing the shorter variants, empty106 Cell Reports 3, 103–115, January 31, 2013 ª2013 The Authorsvector, or Iso-1 K123>A did not show enhanced proliferation
rate in comparison to Iso-1 (Figure S2D). Altogether, these
results suggest that S6K1 short kinase inactive isoforms pro-
mote transformation of MCF-10A cells.
Expression of S6K1 Short Isoforms Enables Growth-
Factor-Independent Three-Dimensional Acini
Formation and Elevates 4E-BP1 Phosphorylation
The immortal breast epithelial cells MCF-10A possess the ability
to grow into spheroid structures (acini) when grown on matrigel.
To study the effects of S6K1 isoforms on growth of three-dimen-
sional (3D) reconstituted basement membrane cultures, we
seeded MCF-10A cells transduced with S6K1 isoforms in the
presence or absence of growth factors necessary for acini
formation in MCF-10A cells (Arias-Romero et al., 2010). Cells
overexpressing S6K1 truncated isoforms, as well as the
kinase-dead version of Iso-1, formed large, hyperproliferative
3D structures (Figures 3A–3C) with slight morphological disrup-
tion (Figure S3A), evenwhen grown in the presence of only one of
the growth factors. This suggests that S6K1 isoforms can
replace the strong proliferative signal provided by either
epidermal growth factor (EGF) or insulin/insulin growth factor
(IGF)-1. This observation is further underscored by the fact that
the kinase active isoform of S6K1 (Iso-1) failed to support
growth-factor-independent acinus formation and may even
inhibit basal proliferation in matrigel (Figures 3A, 3B, and S3A).
Insulin/IGF-1 and EGF activate their corresponding receptors
leading to activation of several mitogenic signaling cascades,
among them the Ras-Raf-MAPK-ERK and the PI3K-Akt-mTOR
pathways (Shaw and Cantley, 2006; Yuan and Cantley, 2008;
Mendoza et al., 2011). We hypothesized that S6K1 short iso-
forms affect acinus proliferation by activating the insulin/IGF-1
and EGF signaling downstream of the receptors, bypassing the
need for growth factor activation (Figures 3A and 3B). Thus, we
sought to investigate the activities of these signaling pathways.
We measured the phosphorylation state of known downstream
effectors of these pathways: Akt, ERK, and 4E-BP1 (Shaw and
Cantley, 2006; Yuan and Cantley, 2008; Mendoza et al., 2011)
in MCF-10A cells overexpressing S6K1 isoforms with and with-
out growth factor activation. We found that overexpression of
S6K1 kinase inactive isoforms stimulated the phosphorylation
of 4E-BP1, even under serum starvation conditions (Figures
3D, 3E, and S3D). Under these conditions, we observed only a
slight and inconsistent activation of Akt or ERK (Figures S3B–
S3D). Notably, while overexpression of S6K1 Iso-1 failed to
increase 4E-BP1 phosphorylation under serum starvation condi-
tions compared to cells transduced with empty vector (Figures
3D, 3E, and S3D), knockdown of this isoform in MCF-10A cells
increased 4E-BP1 phosphorylation (Figures 3F and 3G), sup-
porting the notion that Iso-1 plays an opposite role than S6K1
kinase inactive isoforms. Thus, the increased level of 4E-BP1
phosphorylation we observed, even in serum- and growth-
factor-deprived cells, may contribute to the transforming pheno-
type of cells harboring S6K1 short isoforms (Figures 2C–2E, 3A,
3B, and S2C). Moreover, 4E-BP1 phosphorylation is higher in
most breast cancer cells compared to immortal nontransformed
cells (Avdulov et al., 2004) in correlation with elevated levels of
S6K1 short isoforms (Figures 1B, 1C, S1A, and S3E).
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Figure 3. S6K1 Inactive Isoforms Enable
Growth-Factor-Independent 3D Growth of
MCF-10A Cells and Enhance 4E-BP1 Phos-
phorylation
(A–C) Phase images of MCF-10A cells transduced
with the indicated retroviruses seeded in matrigel
as described in Experimental Procedures, in the
absence of EGF (A) or insulin (B) or in the presence of
both (C). Cells were allowed to grow for 2 weeks to
form acini structures. These results were obtained in
at least three individual experiments.
(D–G) Total protein was isolated from cells and
subjected to western blotting using the indicated
antibodies.
(D and E) MCF-10A-transduced cells described
above were seeded in six-well plates (3 3 105 cells/
well). Cells were starved for 24 hr and then induced
with EGF (D) or IGF-1 (E) for 4 hr. Fold increase of 4E-
BP1 was normalized (phosphorylated/total protein
levels) to that of untreated (starved) pB() (empty
vector), which was arbitrarily set at 1 (quantitation
values are shown under each panel).
(F) MCF-10A cells were transduced with the indi-
cated retroviruses expressing empty vector (mlp[])
or the indicated S6K1 Iso-1-specific shRNAs (Karni
et al., 2007).
(G) MCF-10A cells transduced with the indicated
retroviruses as described in (F) were grown for
24 hr in the presence of 0.5% or 5% serum. Arrows
show the phosphorylation states of 4E-BP1, where
gamma is the fully phosphorylated form. b-actin was
analyzed as a loading control.
See also Figure S3.S6K1 Iso-1 Inhibits Ras-Induced Transformation In Vitro
and In Vivo
Our results, unexpectedly, indicated that the full-lengthS6K1 Iso-
1 did not support growth-factor-independent acinus formation,
as opposed to the short isoforms (Figures 3A–3C). To further
study the possibility that S6K1 Iso-1 acts as a tumor suppressor,
we silenced its expression in the immortal MCF-10A cell lineCell Reports 3, 103–11using Iso-1-specific small hairpin RNA
(shRNAs) (Karni et al., 2007) (Figure 3F).
We measured reduced phosphorylation of
mTOR S2448, a known substrate of p70
S6K1 (Holz and Blenis, 2005; Chiang and
Abraham, 2005) in these cells (Figure 3F).
Knockdown of S6K1 Iso-1 in MCF-10A
cells increased both colony formation in
soft agar and acinus number and size in
matrigel (Figures 4A and S4C). Similar
results were obtained using NCI-H460
lung carcinoma cells (Figures S4A and
S4B). Even though overexpression of Iso-
1 did not significantly decrease cell motility
(Figures 2Dand2E), its knockdown inMCF-
10A cells was sufficient to increase motility
(Figure S4D).
To examine if Iso-1 can suppress the
oncogenic potential of transformed cells,we coexpressed S6K1 Iso-1 with an active RAS mutant (H-
RasV12) in MCF-10A cells (Figure S4E). Cells coexpressing the
kinase active S6K1 isoform (Iso-1) and oncogenic RAS formed
fewer and smaller colonies in soft agar compared to cells coex-
pressing Ras and empty vector, suggesting that S6K Iso-1
possesses tumor-suppressive activity (Figure 4B). Moreover,
cells coexpressing Iso-1/Ras did not gain the spindle/5, January 31, 2013 ª2013 The Authors 107
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Figure 4. S6K1 Iso-1 Knockdown Increases
Transformation and Its Overexpression
Blocks RAS-Induced Transformation
In Vitro and In Vivo
(A) MCF-10A pools of cells were transduced as in
(Figure 3F) and seeded into soft agar in duplicates,
and colonies were allowed to grow for 14 days.
Data represent the average number ± SD of
colonies per well. n = 2.
(B) MCF-10A cells were transduced with retrovi-
ruses encoding pB() empty vector or S6K1 Iso-1
followed by transduction with an active Ras
mutant (H-Rasv12). Cells were seeded into soft
agar in duplicates, and colonies were allowed to
grow for 14 days.
(C) MCF-10A pools of cells transduced with the
indicated retroviruses as in (B) were photographed
24 hr after seeding (3100 magnification).
(D) RAS-transformed MCF-10A cells expressing
empty vector (pB[]) or S6K1 Iso-1 were injected
into NOD-SCID mice (2 3 106 cells/injection).
Tumor volume was measured weekly and tumor
growth curve was calculated as described in
Experimental Procedures; error bars indicate SD
of eight tumors. n/n = number of tumors per
number of injections.
(E) Ras-transformed MCF-10A cells expressing
the indicated retroviruses as described in (B). Total
protein from stable pools was extracted and
subjected to western blotting. The membranes
were probed with the indicated antibodies. b-actin
was analyzed as a loading control.
See also Figure S4.fibroblastic shape that is characteristic of cells transformed with
an oncogene such as Ras (Janda et al., 2002) (Figure 4C). The
same cell pools were injected subcutaneously into NOD-SCID
mice. Supporting the results in vitro, we found that RAS-trans-
formed cells coexpressing Iso-1 did not form tumors in vivo
(zero tumors formed of eight injections) as opposed to the empty
vector (eight of eight tumors formed) (Figures 4D and S4F). 4E-
BP1 phosphorylation levels were lower in cells coexpressing
Iso-1 and H-RasV12 than in cells expressing H-RasV12 alone
(compare the g bands in Figure 4E). Moreover, cells coexpress-
ing Iso-1 and RasV12 showed about 20% decrease in Cap-
dependent translation in correlation with the decreased phos-
phorylation of 4E-BP1 (Figure S4G). Taken together, these
data suggest that S6K1 Iso-1 is a putative tumor suppressor.
S6K1 Short Isoforms Bind mTORC1 and Enhance
Cap-Dependent Translation and Mcl-1 Expression
We hypothesized that S6K1 short isoforms might directly bind
and activate mTORC1. To test this possibility, we cotransfected
myc-tagged mTOR and T7 tagged Iso-1 or Iso-2 (as a represen-108 Cell Reports 3, 103–115, January 31, 2013 ª2013 The Authorstative of the short isoforms). Immunopre-
cipitation of transfected S6K1 with anti-
T7 antibody revealed that only S6K1
Iso-2 interacts with mTOR (Figures 5A
and 5B). The fact that we did not see an
interaction between S6K1 Iso-1 andmTORmight be explained by T389 phosphorylation of S6K1 (Fig-
ure 5B). This phosphorylation activates S6K1 Iso-1 (Kim et al.,
2002), leading to its release from mTORC1 (Holz et al., 2005).
Cells overexpressing S6K1 short inactive isoforms showed
elevated levels of cap-dependent translation under serum star-
vation conditions as measured by a reporter gene measuring
Cap- versus IRES-mediated translation from the same transcript
(Figures 5C and 5D). Indeed, Iso-1 overexpressing MCF-10A
cells exhibited only a slight decrease in 4E-BP1 phosphorylation
that was consistent with a slight decrease of cap-dependent
translation, compared to cells expressing empty vector (Figures
3D, 3E, and 5D). Moreover, on the background of H-RasV12
transformation, Iso-1 decreased both 4E-BP1 phosphorylation
and cap-dependent translation (Figures 4E and S4G), sug-
gesting that Iso-1 tumor-suppressive effect can be clearly
detected on the background of a strong oncogene such as
mutant Ras but not in a nontransformed cell system such as
MCF-10A cells.
We next examined if S6K1 short isoforms alter the expres-
sion of proteins known to be controlled by mTORC1-4E-BP1
Figure 5. S6K1 Kinase Short Isoforms
Interact with mTOR, Enhance Cap-Depen-
dent Translation, and Increase Mcl-1
Expression
(A and B) HEK293 cells were cotransfected with
myc-tagged mTOR and the indicated T7-tagged
S6K1 isoforms. Whole-cell lysates were examined
for construct expression (A) and for immunopre-
cipitation of T7-tagged S6K1 isoforms (B). Myc-
taggedboundmTORandT7-taggedS6K1 isoforms
weredetectedby immunoblottingusinganti-mycor
monoclonal antibody against the N0 terminus of
S6K1, respectively. The first two left lanes represent
anti-T7 anibody alone and pull down from un-
transfected HEK293 cells, respectively.
(C) Schematic representation of pLPL Cap-
Renilla-IRES-Luciferase bicistronic dual reporter
vector (Gerlitz et al., 2002).
(D) MCF-10A cells were cotransfected with dual
reporter vector (C) and with the indicated S6K1
isoforms and starved for serum and growth
factors for 24 hr posttransfection. Cap-dependent
translation (Renilla luciferase activity) and IRES-
mediated translation (Firefly luciferase activity)
were measured (n = 4 experiments,*p = 0.019,
**p = 0.008, ***p = 0.033).
(E) MCF-10A cells were transduced with retrovi-
ruses encoding for the indicated S6K1 isoforms.
Transductants (3 3 105) were seeded in six-well
plates and starved for 24 hr for serum and growth
factors. After western blotting, the membranes
were probed with the indicated antibodies.
b-catenin was analyzed as a loading control.
(F) MCF-10A cells described in (Figure 3F) were
seeded (3 3 105 cells/well) in a six-well plate.
Twenty-four hours later, cells were lysed and total
protein was extracted and separated by SDS-
PAGE. The membranes were probed with the
indicated antibodies. b-actin was analyzed as a
loading control.
See also Figure S5.translational regulation and can contribute to cell transformation.
One such protein isMcl-1 (Hsieh et al., 2010), a key antiapoptotic
protein that was shown to be translationaly controlled by
mTORC1 (Mills et al., 2008). We found that Mcl-1 protein levels
are elevated inMCF-10A cells overexpressing S6K1 kinase inac-
tive isoforms, but not Iso-1 or empty vector (Figure 5E). Interest-
ingly, Mcl-1 was also elevated by Iso-1 knockdown (Figure 5F).
S6K family consists of two kinases, S6K1 and S6K2 (RPS6KB1
and RPS6KB2, respectively) (Lee-Fruman et al., 1999), that are
known to have redundant activities (Nardella et al., 2011; Pende
et al., 2004). We did not detect any changes in S6K2 protein
levels in either Iso-1 knockdown or S6K1 kinase inactive iso-
forms overexpression (Figures S5A and S5B), indicating that
the biological effects we observe are due to up or downregula-
tion of S6K1 Iso-1 or the short S6K1 isoforms.
Loss of S6K1/2 Enhances Cap-Dependent Translation,
Mcl-1 Expression, and Transformation
In order to establish definitive proof that S6K1 Iso-1 is a tumor
suppressor and to rule out any possible compensation or inter-
ference by S6K2, we analyzed S6K1 and S6K2 double-knockoutC(DKO) mouse embryonic fibroblasts (MEFs) (Figure 6A) (Dowling
et al., 2010; Pende et al., 2004). Consistent with our previous
results, serum-starved S6K DKO MEFs showed elevated phos-
phorylation levels of 4E-BP1 (Figure 6A). In addition, S6K DKO
MEFs formed significantly higher number of colonies in soft
agar and also presented 5-fold increase in cap-dependent
translation, indicating that these cells are transformed (Figures
6B and 6C). Furthermore, western blot analysis of S6K DKO
MEFs revealed high levels of expression of Mcl-1 (Figure 6D)
in agreement with what was observed in Iso-1 knockdown in
MCF-10A cells (Figure 5F). The fact that the DKO cells show
minor/negligible mTOR phosphorylation (Figure 6A) and no S6
phosphorylation (Figure S2F), but were transformed, supports
the notion that mTOR S2448 phosphorylation is not essential
for its ability to phosphorylate 4E-BP1.
Expression of Iso-1 in S6K DKO MEFs (Figure S2E) partially
reduced cap-dependent translation, colony survival, and growth
of colonies in soft agar showing that Iso-1 harbors tumor-
suppressive ability (Figures 6E–6G). The transformed phenotype
of S6K DKO MEFs was not completely reversed by the ectopic
expression of S6K1 Iso-1, probably due to the absence ofell Reports 3, 103–115, January 31, 2013 ª2013 The Authors 109
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Figure 6. Loss of S6K1/2 Enhances Cap-
Dependent Translation, Mcl-1 Expression,
and Transformation
(A) Wild-type (WT) or S6K1 and S6K2 DKO MEFs
were seeded at 80% confluency and serum
starved for 5 hr. Total protein was extracted and
subjected to western blotting. The membranes
were probed with the indicated antibodies.
(B) WT and DKO MEFs were seeded into soft agar
in triplicates and colonies were allowed to grow for
14 days. Data represent the average number ± SD
of colonies per well. n = 3. The results shown are
a representative experiment out of three individual
experiments.
(C) WT and DKO MEFs were transfected with
dual reporter vector (Cap-Renilla-IRES-Luciferase
described in Figure 5C). Twenty-four hours post-
transfection cells were serum starved for another
24hr.Cap-dependent translation (Renilla luciferase
activity) and IRES-mediated translation (Firefly
luciferase activity) were measured (data represent
the average number ± SD of n = 6 experiments).
(D) Total protein from WT and DKO MEFs
described in (A) was separated by SDS-PAGE.
After western blotting, the membranes were pro-
bed with the indicated antibodies.
(E) S6K1 and S6K2 DKO MEFs cells transduced
with retroviruses encoding for empty vector
(pB[]) or S6K1 Isoform-1(Iso-1) were transfected
with dual reporter vector (Cap-Renilla-IRES-
Luciferase) 24 hr posttransfection cells were
serum starved for another 24 hr. Cap-dependent
translation (Renilla luciferase activity) and IRES-
mediated translation (Firefly luciferase activity)
were measured (n = 3 experiments,*p < 0.004).
(F) MEF cells described in (E) were seeded (200
cells/well) in six-well plates and grown for 14 days.
Colonies were fixed and stained with methylene
blue.
(G) MEF cells described in (E) were seeded into
soft agar in triplicates and colonies were allowed
to grow for 14 days. Data represent the average
number ± SD of colonies per well. n = 3. The
results shown are a representative experiment out
of three individual experiments.S6K2 in this cell system that might contribute to the tumor-
suppressive phenotype of S6K1.
The Oncogenic Activities of S6K1 Short Isoforms Are
Mediated by mTORC1 Inactivation of 4E-BP1
S6K1 short isoforms activated mTORC1 as measured by 4E-
BP1 phosphorylation (Figures 3D, 3E, and S3D). We next exam-
ined, using two complementary strategies, if this activation is
required for their oncogenic activities: (1) inhibition of mTORC1
by the pharmacological inhibitor rapamycin, and (2) expression
of a phosphorylation-defective 4E-BP1, which is mutated in its
phosphorylation sites and cannot dissociate from eIF4E upon
mTORC1 activation (Avdulov et al., 2004; She et al., 2010).
We transduced MCF-10A cells expressing the mouse S6K1
short isoform (Iso-2) with phosphorylation-defective 4E-BP1
(4E-BP15A or 4E-BP14A), where each of the five (or four) insulin
and rapamycin-responsive 4E-BP1 phosphorylation sites have
been mutated to alanine (Hsieh et al., 2010).110 Cell Reports 3, 103–115, January 31, 2013 ª2013 The AuthorsCoexpression of both Iso-2 and mutant 4E-BP1 decreased
colony formation in soft agar 2-fold relative to cells expressing
Iso-2 alone (Figures 7A, 7B, S6A, and S6B). Similarly, rapamycin
reduced the number of colonies formed in soft agar in cells over-
expressing Iso-2 to the background level of cells expressing
empty vector (Figure 7B). These results suggest that mTORC1
activation and 4E-BP1 phosphorylation play a major role in the
oncogenic capabilities of S6K1 short isoforms.
Expression of mutant 4E-BP1 together with Iso-2 also partially
decreased cell motility compared to cells expressing Iso-2 alone
(Figures 7C and 7D).
Next, we investigated whether 4E-BP1 phosphorylation is im-
portant for Iso-2-mediated growth-factor-independent 3D prolif-
eration inmatrigel. Expression of 4E-BP15A strongly inhibited Iso-
2’s ability to induce growth-factor-independent acinus formation
in matrigel (Figure 7E). Taken together, our results suggest that
the mechanism of action of S6K1 short isoforms is mediated
mostly by 4E-BP1 phosphorylation through mTORC1 activation.
Figure 7. 4E-BP1 Inactivation and mTORC1
Activity Is Required for the Oncogenic
Activities of S6K1 Short Isoforms
(A) MCF-10A cells were cotransduced with retro-
viruses encoding for empty vector pWZl-Hygro
(pW) or pW-4E-BP1 phosphorylation defective
mutant in which all five phosphorylation sites were
mutated to alanine (4E-BP15A) (Hsieh et al., 2010)
and empty vector pBABE (pB[]) or pB- Iso-2.
Total protein from stable pools was extracted and
separated by SDS-PAGE. Membranes were pro-
bed with monoclonal antibodies against 4E-BP1
or S6K1 to detect the endogenous and exogenous
isoforms. b-actin was analyzed as a loading
control.
(B) MCF-10A pools of cells transduced with the
indicated retroviruses as in (A) were seeded into
soft agar in duplicates, with or without 100 nM
rapamycin, and colonies were allowed to grow
for 14 days. Colonies from ten fields of each well
were counted, and representative fields of colo-
nies were photographed in phase image (3100
magnification). Data represent the average
number ± SD of colonies per well. n = 2.
(C) MCF-10A pools of cells transduced with the
indicated retroviruses as in (A) were stimulated to
migrate by physical wounding of cells seeded in
monolayer. Data represent the average number of
quantified wound area and SD from three indi-
vidual experiments.
(D) Representative images of the wound area of
cells described in (C).
(E) Phase images of MCF-10A cells transduced
with the indicated retroviruses seeded in matrigel.
Cells were allowed to grow for 2 weeks to form
acini structures.
(F) A proposed model of mTORC1 regulation by
S6K1 isoforms. In nontransformed cells upon
mitogen stimulation, S6K1 Iso-1 is activated by
mTORC1 and generates a feedback signal loop
resulting in phosphorylation of mTOR at S2448
in the repressor domain. This might attenuate
mTOR’s ability to phosphorylate and repress 4E-
BP1 leading to decreased cap-dependent trans-
lation. Other cellular substrates might contribute
to the tumor-suppressive activity of Iso-1 inde-
pendently of cap-dependent translation (left
panel). In transformed cells S6K1 short isoforms
are upregulated, bindmTORC1 and increase its activity. mTORC1 activation leads to enhanced 4E-BP1 phosphorylation, cap-dependent translation elevation of
the antiapoptotic protein Mcl-1 and other proliferating or anti apoptotic proteins and increased cell survival and transformation (right panel).
See also Figure S6.DISCUSSION
We have previously shown that mouse S6K1 is alternatively
spliced to form a short isoform (Iso-2), which is essential for
the oncogenic activity of the splicing factor oncoprotein
SRSF1(Karni et al., 2007). Here, we report that in human cells
S6K1 has two alternatively spliced short isoforms that are over-
produced in breast cancer cell lines and tumors. Furthermore, all
of S6K1 short splicing variants lack an autoinhibitory C terminus
domain (Ali and Sabatini, 2005) and half of the kinase domain and
do not exhibit kinase activity, at least on the known S6K1
substrate rpS6 (Figures 2A and S2E–S2G). Overexpression ofCmouse or human S6K1 short isoforms enhanced transformation,
anchorage-independent growth, cell motility, and growth-factor-
independent 3D acinus formation of human breast epithelial cells
(Figures 2, 3A–3C, S2C, and S3A). Surprisingly, the long, kinase
active S6K1 isoform (Iso-1) inhibited 3D acinus formation and
reduced 4E-BP1 phosphorylation, cap-dependent translation,
and transformation in vitro and in vivo, demonstrating many
properties that characterize a tumor suppressor. Our results
suggest that only S6K1 short isoforms, but not Iso-1, interact
with and activate mTORC1 leading to elevated 4E-BP1 phos-
phorylation, enhanced cap-dependent translation, and upregu-
lation of the antiapoptotic protein Mcl-1. Inhibition of mTORC1ell Reports 3, 103–115, January 31, 2013 ª2013 The Authors 111
or 4E-BP1 phosphorylation can partially reverse the oncogenic
activity of S6K1 short isoforms, suggesting that their oncogenic
properties are at least in part mediated by this pathway.
A Switch in RPS6KB1 Alternative Splicing Upregulates
Oncogenic Isoforms in Breast Cancer
We found that many breast cancer cell lines and tumors switch
the splicing of RPS6KB1 to elevate the human short isoforms
of S6K1 h6A and h6C (Figures 1B–1D, S1F, and S1G). There
are several documented examples of an alternative splicing
switch that induces a prooncogenic isoform at the expense of
a tumor-suppressive isoform. In many cancers, tumor-suppres-
sive isoforms are downregulated, while prooncogenic ones are
upregulated (David and Manley, 2010). We found that while
all the short S6K1 isoforms, as well as the kinase-dead form
of Iso-1, induced anchorage-independent growth, enhanced
motility, and growth-factor-independent 3D acinus formation in
matrigel, the active S6K1 isoform (Iso-1) did not (Figures 2, 3,
and S2C). Moreover, in most of these assays Iso-1 showed an
opposite effect, indicating that these splicing isoforms possess
antagonistic activities. Several lines of evidence suggest that
Iso-1 acts as a functional tumor suppressor. (1) When coex-
pressed with an active RasV12 mutant, Iso-1 inhibited Ras-
induced transformation in vitro and in vivo (Figure 4), suggesting
it possesses an antitumorigenic activity. (2) Iso-1 knockdown in
MCF-10A cells induced transformation, colony formation in soft
agar, acinus formation, increased motility, and elevated Mcl-1
levels (Figures 4A, 5F, S4C, and S4D). (3) Loss of S6K1 and
S6K2 had dramatic effect on cellular transformation, as immor-
talized MEFs from S6K1/2 DKO mice were transformed, formed
large numbers of colonies in soft agar, and showed increased
levels of the antiapoptotic protein Mcl-1 (Figure 6), which is
translationally regulated by mTORC1(Hsieh et al., 2010). (4) Re-
introduction of S6K1 Iso-1 partially inhibited the transformed
phenotypes of S6K1/2 DKO cells indicating that Iso-1 possesses
tumor-suppressive activities, but might also require the pres-
ence of S6K2 in these cells to restore its full capability as an anti-
tumorigenic protein (Figure 6). It has been shown previously that
S6K1 is required for insulinoma development in a mouse model
where an active Akt mutant (Myr-Akt) was overexpressed in
pancreatic beta cells under the insulin promoter (Alliouachene
et al., 2008). Similarly, S6K1 deletion on the background of
PTEN+/ and low expression of S6K2 in pheochromocytoma
cells impaired adrenal tumorigenesis (Nardella et al., 2011). In
both of these reports, the cancer was induced by activation of
the same pathway (PI3K-Akt) and in a specific tissue. It is
conceivable that under other experimental settings the outcome
might be different, as already demonstrated for S6K1 deletion in
other tissues (Nardella et al., 2011). The lack of an effect on tumor
development in the latter cases is possibly due to redundancy
between S6K1 and S6K2. Moreover, to the best of our
knowledge, no study has directly shown that overexpressed or
mutated S6K1 or S6K2 acts as an oncogene. Hence, the present
report provides direct evidence for the pro- and antitumorigenic
effects of stable knockdown or overexpression of S6K1 long iso-
form (Iso-1), respectively. It should be noted that the pro-onco-
genic effect of Iso-1 knockdown does not involve S6K2, as the
latter remained unchanged (Figure S5). Notably, the catalytic112 Cell Reports 3, 103–115, January 31, 2013 ª2013 The Authorsactivity of S6K1 is essential for its tumor-suppressive activity,
as the kinase-dead point mutant completely abrogated this
activity. In addition, the fact that Iso-1 inhibited Ras transforma-
tion, but only partially inhibited cap-dependent translation raises
the possibility that Iso-1 phosphorylates additional substrates
other than those in the mTOR pathway, that contribute to
its tumor suppressor activity independently of cap-dependent
translation. Importantly, S6K1 short isoforms are catalytically
inactive and did not induce phosphorylation of the known
S6K1 substrates, the ribosomal protein S6 or mTOR itself in an
in vitro kinase assay and upon transfection into cells (Figures
5A, 5E, S2E–S2G, and S3C). Altogether, these results suggest
that Isoform-1 of S6K1 has tumor-suppressive properties, while
the short isoforms are pro-oncogenic. Our results suggest that
the gain of h6A and h6C observed in breast cancer cells and
tumors is a mechanism to switch off a tumor-suppressive iso-
form and to turn on an oncogenic one.
RPS6KB1 Splicing Isoforms Modulate the Activity of
mTORC1
Surprisingly, we found that most S6K1 short isoforms activated
mainly 4E-BP1 phosphorylation without a significant activation
of Akt or ERK and in a growth-factor-independent manner
(Figures 3 and S3). In accordance with increased 4E-BP1 phos-
phorylation, cells expressing S6K1 short isoforms showed ele-
vated cap-dependent translation and upregulation of Mcl-1,
while Iso-1-expressing cells showed low or basal cap-depen-
dent translation, similar to the control cells expressing empty
vector or reduced cap-dependent translation in Ras-trans-
formed cells (Figures 5 and S4G). Moreover, loss of S6K1 and
S6K2 enhanced cap-dependent translation in MEF cells that
was partially inhibited by S6K1 Iso-1 reintroduction (Figure 6),
indicating that S6K1 and S6K2 activities suppress cap-depen-
dent translation and transformation (Figure 6). Although sur-
prising, previous studies support this result: Cells from a knockin
mouse of a mutant S6 gene (rpS6P/), where all five phosphor-
ylation sites were replaced to alanines, showed a 2-fold increase
in global translation as measured by methionine incorporation
and a 2-fold increase in proliferation rate as compared to
MEFs from WT littermates (Ruvinsky et al., 2009). Combining
these two findings, both inactivation of the ‘‘kinase’’ (S6K1/2
DKO) and inhibition of phosphorylation of the substrate
(rpS6P/) gave similar results of increased translation. This
suggests that S6 phosphorylation might inhibit rather than
increase translation. Other studies did not find reduced transla-
tion upon S6K1/2 loss, even though they did not observe in-
creased translation (Mieulet et al., 2007). These results suggest
that the growth-factor-independent growth observed in matrigel
(Figure 3) could be explained by the ability of S6K1 short iso-
forms to activate mTORC1 that, in turn, inactivates 4E-BP1
even under low nutrient conditions. Enhanced cap-dependent
translation contributes to cancer development by elevating the
translation of several oncogenes and antiapoptotic genes such
as Mcl-1, Bcl-X, MDM2, HIF-1a, b-catenin, c-myc, cyclin D1,
and others, which are translationally regulated by cap-depen-
dent translation and the mTORC1 pathway (Hsieh et al., 2010;
Karni et al., 2002; Karni et al., 2005; Mamane et al., 2004).
We found that, at least in the case of the antiapoptotic protein
Mcl-1, overexpression of S6K1 short isoforms, Iso-1 knockdown
or S6K1/2 knockout enhanced its expression (Figures 5E, 5F,
and 6D). To examine if S6K1 short isoforms can interact with
mTOR, we coexpressed mTOR with S6K1 Iso-1 or Iso-2 and
found that only the short isoform could pull down mTOR,
whereas Iso-1 did not, even though its expression was much
higher (Figures 5A and 5B).
The Oncogenic Activities of S6K1 Short Isoforms Are
Partly Mediated through 4E-BP1 and mTORC1
Activation
We examined the contribution of mTORC1-4E-BP1 axis to S6K1
short-isoform-mediated oncogenesis and found that inhibition of
eIF4E/4E-BP1 dissociation greatly inhibited motility, anchorage-
independent growth, and growth-factor-independent acinus
formation in matrigel (Figures 7 and S6). These results suggest
that most of the oncogenic effects of S6K1 short isoforms are
mediated by mTORC1 activation. However, we cannot rule out
the possibility that S6K1 short isoforms affect other oncogenic
signaling pathways as suggested by the fact that expression of
a dominant-negative 4E-BP1 did not fully suppress colony
formation in soft agar and motility induced by S6K1 short iso-
forms. These results also suggest that S6K1 is not only a
substrate of mTOR, but that it may also modulate the activity
of mTOR increasing 4E-BP1 phosphorylation when S6K1 short
isoforms are elevated (Figures 3 and S3D). In addition, S6K1
Iso-1 can phosphorylate mTOR at serine 2448 (Figures 3F, 5A,
and 6A), although the consequences of this phosphorylation
onmTOR activity are not fully understood (Chiang and Abraham,
2005; Holz and Blenis, 2005). S6K1 short isoforms cannot be
phosphorylated by mTOR at threonine 389 and by phosphoino-
sitide-dependent kinase 1 (PDK1) at threonine 229, as they lack
both phosphorylation sites. However, both Iso-1 and the short
isoforms should be able to bind mTORC1, since all of them
contain the Raptor binding motif called mTOR-signaling (TOS
motif) (Schalm and Blenis, 2002). Thus, while Iso-1 activity
responds to mitogenic and nutritional stimuli, as well as energy
status, the short isoforms are refractory to any of these signals,
yet they can still affect mTORC1. Indeed, our data suggest that
these short isoforms transmit through mTORC1 activation,
a constitutive mitogenic/metabolic signal, even in the absence
of growth factors (Figures 3 and S3). In addition, S6K1 short iso-
forms cannot induce mTOR S2448 phosphorylation, as they lack
a functional kinase domain and are catalytically inactive (Figures
5A and S2E–S2G). Thus, our current hypothesis is that Iso-1
phosphorylates mTOR and inhibits cap-dependent translation
and transformation. Iso-1 also phosphorylates other cellular
substrates that might lead to suppression of transformation. In
contrast, the short isoforms bind to the same or other cellular
targets and thereby induce opposite effects. S6K1 short iso-
forms can bind directly to mTORC1 and enhance its activity
possibly by competing with Iso-1 for mTOR binding (Figure 7F).
Nevertheless, the mechanism by which S6K1 short isoforms
activate mTOR is yet to be determined.
We have discovered alternatively spliced variants of the gene
encoding S6K1. Our findings provide additional insight into the
oncogenic switch that can be caused by alternative splicing.
Furthermore, another mode of mTORC1 activation is identifiedCin this study, which may open a new direction in manipulating
mTORC1 activity for cancer therapy. In addition, we show that,
the balance between S6K1 short isoforms and Iso-1 is tipped
toward those short isoforms in most tumors examined, suggest-
ing that this splicing event can be a useful marker for breast
cancer development. Moreover, since S6K1 short isoforms acti-
vate mTORC1 and this activation is important for tumorigenesis,
we expect that the newly approved active site mTOR inhibitors
will act more efficiently on tumors where the S6K1 alternative
splicing switch has occurred.
EXPERIMENTAL PROCEDURES
Cells
NIH 3T3 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% (v/v) calf serum (BS), penicillin, and streptomycin.
Human breast cells, MCF-10A, were grown in DMEM/F12 supplemented
with 5% (v/v) horse serum, 50 ng/ml EGF, 10 mg/ml insulin, 0.5 mg/ml hydrocor-
tisone, 100 ng/ml cholera toxin, penicillin, and streptomycin (Arias-Romero
et al., 2010). MCF-7, MDA-MB-231, and HEK293 cells were grown in
DMEM,HMLE cells were grown inMEBM/DMEM/F12, andMDA-MB-468 cells
were grown in Leibovitz-F12, supplemented with 10% (v/v) fetal bovine serum,
penicillin, and streptomycin. SUM159 cells were grown in Ham’s F12 with 5%
(v/v) calf serum, 5 mg/ml insulin, and 1 mg/ml hydrocortisone. S6K1/2 double-
knockout MEFs were generated as described in Pende et al. (2004) and were
immortalized by the 3T3 protocol as described in Dowling et al. (2010).
Stable Cell Lines
NIH 3T3 and MCF-10A cells were infected with pBABE-puro retroviral vectors
encoding T7-tagged S6K1 isoforms human and mouse cDNAs as described
(McCurrach and Lowe, 2001). Infected cells were selected with puromycin
(2 mg/ml) or hygromycin (200 mg/ml) for 72–96 hr. In the case of double infection
with pWZL-hygro-Ras (McCurrach and Lowe, 2001), cells were treated with
hygromycin for 72 hr after selection with puromycin. In the case of infection
with MLP-puro-shRNAs vectors, MCF-10A cell transductants were selected
with puromycin (2 mg/ml) for 96 hr.
Immunoblotting
Cells were lysed in Laemmli buffer and analyzed for total protein concen-
tration as described (Golan-Gerstl et al., 2011). Primary antibodies were as
follows: Sigma: b-catenin (1:2,000) phospho-ERK (1:10,000 T202/Y204);
Santa Cruz: b-actin (1:200), total Akt (1:200 sc1619), GAPDH (1:1,000
sc25778), Myc (1:1,000 sc40); Novagen: T7 tag (1:5,000); BD Trunsduction
Laboratories: total S6K1-anti-p70; Cell Signaling Technologies: total ERK1/2
(1:1,000); phospho-4E-BP1 Thr70 (1:1,000 #2855), 4E-BP1 (1:1,000 #9452),
phospho-S6K1 Thr389 (1:1,000 #9205), p-S6 ser240/244 (1:1,000 #2215), total
S6 (1:1,000 #2217), phospho-Akt ser473 (1:1,000 #9271), RAS (1:1,000
#3339), p-S2448-mTOR (1:1,000 #2972), secondary antibodies: HRP-conju-
gated goat anti-mouse, anti-rabbit, or anti-goat IgG (H+L) (1:10,000 Jackson
Laboratories).
Immunoprecipitation
HEK293 cells were transfected with myc-mTOR and pCDNA3-T7-Iso-2/h6A/
h6C/pCDNA3 or pCDNA-T7-Iso-1 S6K1 with empty pCDNA. Forty-eight hours
after transfection, cells were lysed in CHAPS buffer as described (Sarbassov
et al., 2004). After protein quantitation, 1 mg of anti-T7 antibody bound to
40 ml of 50% protein G-Sepharose was incubated with 800 mg of total protein
lysate overnight. After washing four times with CHAPS buffer and beads were
incubated with 50 ml of 2 3 Laemmli buffer and separated by SDS-PAGE.
Colony-Survival Assay
S6K1/2DKOMEFcell populationswere transducedwith retroviruses encoding
for empty pB() vector or T7-Iso-1 S6K1. After selection, cells were seeded
sparsely (200 cells/well of six-well plates) andwere grown for 14 days. Colonies
were fixed and stained with methylene blue as described (Karni et al., 2007).ell Reports 3, 103–115, January 31, 2013 ª2013 The Authors 113
Dual Luciferase Reporter Assay
MCF-10A cells were cotransfected using Fugene 6 (Roche) with the dual
reporter vector pLPL (Cap-Renilla-IRES-Luciferase) (Gerlitz et al., 2002) and
the indicated S6K1 isoforms. Cap-dependent translation (Renilla luciferase
activity) and IRES-mediated translation (Firefly luciferase activity) were
measured with the Promega Stop and Glow assay kit according to the manu-
facturer’s instructions.
EGF and IGF-1 Activation
MCF-10A cells (3 3 105) were seeded in six-well plates. Twenty-four hours
later, cells where washed with PBS, and the medium was replaced with
a serum and growth factor-free media for 24 hr. Cells were stimulated with
50 ng/ml IGF-1 or 50 ng/ml EGF for 4 hr. After 4 hr, cells were lysed in Laemmli
buffer for western blot analysis.
Anchorage-Independent Growth
Colony formation in soft agar was assayed as described (Karni et al., 2007;
McCurrach and Lowe, 2001). After 14–21 days, colonies from ten different
fields in each of two wells were counted for each transductant pool, and the
average number of colonies per well was calculated. The colonies were
stained as described (Karni et al., 2007; McCurrach and Lowe, 2001).
Growth Curves
MCF-10A cells were infected with the indicated retroviruses. Following selec-
tion, 2,000 or 3,500 cells per well were seeded in 96-well plates and grown in
DMEM/F12 media with 5% or 0.2% horse serum. Cells were fixed and stained
withmethylene blue as described (Karni et al., 1999), and the absorbance at l=
650 nm of the acid-extracted stain was measured on a plate reader (Bio-Rad).
3D Morphogenesis of Mammary Epithelial Cell Assay
MCF-10A cells were infected with the indicated retroviruses. Following selec-
tion,1,500cells perwellwere seeded in96-well plates ingrowth-factor- reduced
matrigel (BD Bioscience, Cat# 25300), as described in Zhan et al. (2008). The
method is also described in Debnath et al. (2003). In some cases, 2.5 or 5 ng/
ml of EGF or 10 mg/ml of insulin was added to assay medium of seeded cells.
Wound-Healing Assay
MCF-10A cells were seeded in a six-well plate until formation of a confluent
monolayer, and a ‘‘wound’’ was created by scratching the monolayer with
a p200 pipette tip as described in Liang et al. (2007). Cells were washed
with PBS and growth medium was replaced to DMEM/F12 media with 5%
horse serum without EGF and insulin. The wound was photographed (3100
magnification) after matching the reference point in a phase contrast micro-
scope and wound area was measured using Photoshop record measurement
analysis tools.
Xenograft Tumor Formation in Mice
Pools of Ras-MCF-10A cells expressing the indicated S6K1 isoforms were in-
jected subcutaneously into the rear flanks of NOD-SCIDmice (23 106 cells per
site in 100 ml of serum-free media containing 0.25 v/v matrigel (BD Bioscience)
using a 26-gauge needle. Tumor growth was monitored as described (Karni
et al., 2007). Veterinary care was provided to all animals by the Hebrew Univer-
sity animal care facility staff in accordance with AAALAC standard procedures
and as approved by the Hebrew University Ethics committee (no. MD-08-
11517-4).
Statistical Analysis
All data presented as histograms refer to a mean value ± SEM of the total
number of independent experiments. An unpaired, two-tailed t test was
used to determine p values for Figures 2C and 5B.
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